Updates on Secukinumab |
Conferences
eMediNexus Coverage from: 
Updates on Secukinumab
Dr Chandrashekhar BS, Bengaluru,  21 January 2019
Coronavirus Live Count Map India

remove_red_eye 834 Views
COVID-19 Vaccine Updates

Coronavirus Protocols

#Dermatology

0 Read Comments                

IL-17 plays a significant role in the immune-pathogenesis of psoriasis.Secukinumab is a fully human monoclonal IgG1-k antibody that selectively binds to and inhibits IL-17A, preventing binding to the IL-17 receptor. Secukinumab, an IL-17 inhibitor, was approved in US: 2015 for moderate-to-severe plaque psoriasis; 2016 for psoriatic arthritis (PsA) and ankylosing spondylitis.FDA approval of secukinumab for moderate-to-severe plaque psoriasis. The updated label includes Secukinumab data in moderat...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now